Combining targeted agents with modern radiotherapy in soft tissue sarcomas

Area of Science:

• Oncology
• Radiation Oncology
• Surgical Oncology

Background:

• Soft-tissue sarcoma (STS) subtypes require tailored treatments, with radiation therapy (RT) crucial for extremity STS local control (>85% 5-year).
• Non-extremity STS has significantly lower local control rates (~50% 5-year), contributing to morbidity and mortality.
• Advancements in RT technology and radiosensitizing agents offer potential to improve outcomes in challenging STS cases.

Purpose of the Study:

• To review current strategies and ongoing research for enhancing RT efficacy in STS.
• To outline a vision for translating preclinical findings into clinical practice for STS treatment.
• To identify targeted agents for combination with RT across diverse STS subtypes and locations.

Main Methods:

• Review of preclinical data, clinical trials, and established management protocols for STS.
• Analysis of biological pathways targeted by RT and radiosensitizing agents (angiogenesis, cell cycle, immune interactions).
• Evaluation of standard STS clinical management (biopsy, neoadjuvant therapy, surgery) as a model for translational research.

Main Results:

• RT efficacy can be modulated by targeting specific biological pathways crucial for STS growth and survival.
• Combination of RT with novel radiosensitizing agents is under investigation to improve local control and survival.
• Preclinical and clinical data suggest potential benefits of combining RT with agents targeting angiogenesis, cell cycle, and immune responses.

Conclusions:

• Optimizing RT delivery and combining it with targeted radiosensitizing agents is essential for improving STS treatment.
• Translational research integrating preclinical insights with clinical STS management is key to developing effective therapeutic strategies.
• Personalized treatment approaches, considering STS subtype and anatomical site, are crucial for enhancing patient outcomes.